# Study of BW-50218 in Healthy Participants

> **NCT07401472** · PHASE1 · RECRUITING · sponsor: **Shanghai Argo Biopharmaceutical Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Healthy Participants Study

## Interventions

- **DRUG:** BW-50218 Injection
- **DRUG:** Saline (0.9% NaCl)

## Key facts

- **NCT ID:** NCT07401472
- **Lead sponsor:** Shanghai Argo Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-12
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07401472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07401472, "Study of BW-50218 in Healthy Participants". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07401472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*